Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Penumbra (NYSE: PEN) announced its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 6:45pm ET / 3:45pm PT.
A live webcast will be available on the company website under Investors > Events and Presentations and will remain accessible for at least two weeks after the event.
Positive
- None.
Negative
- None.
News Market Reaction – PEN
In the Dec 30 session, PEN declined 0.20%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 19 | Conference appearance | Neutral | -1.2% | Piper Sandler healthcare conference presentation with webcast for investors. |
| Nov 05 | Earnings results | Positive | -4.1% | Q3 2025 revenue growth, strong margins, and raised full-year guidance. |
| Nov 03 | Clinical trial data | Positive | -0.5% | STORM-PE trial showed improved outcomes for pulmonary embolism patients. |
| Oct 27 | Clinical trial data | Positive | -2.0% | STORM-PE RCT showed CAVT plus anticoagulation superior to anticoagulation alone. |
| Oct 08 | Investor event setup | Neutral | +0.9% | Scheduled TCT investor event and timing of Q3 2025 earnings release. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive earnings and clinical updates were followed by mild to moderate single-day declines, while scheduling/investor event news saw relatively modest reactions.
Over the last few months, Penumbra highlighted STORM-PE trial successes, investor events, and strong Q3 2025 financials with raised full-year revenue guidance. Despite favorable clinical and earnings milestones, 1-day moves after those releases were often negative. Today’s J.P. Morgan Healthcare Conference appearance continues the pattern of frequent investor-facing events, consistent with prior conference and investor day communications that emphasized clinical data and financial performance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Event: | 44th Annual J.P. Morgan Healthcare Conference |
Date: | Monday, January 12, 2026 |
Time: | 6:45pm ET/3:45pm PT |
A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the event.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
Investor Relations
Penumbra, Inc.
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302640354.html
SOURCE Penumbra, Inc.